Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

نویسندگان

  • Jean Bourhis
  • Jens Overgaard
  • Hélène Audry
  • Kian K Ang
  • Michele Saunders
  • Jacques Bernier
  • Jean-Claude Horiot
  • Aurélie Le Maître
  • Thomas F Pajak
  • Michael G Poulsen
  • Brian O'Sullivan
  • Werner Dobrowsky
  • Andrzej Hliniak
  • Krzysztof Skladowski
  • John H Hay
  • Luiz H J Pinto
  • Carlo Fallai
  • Karen K Fu
  • Richard Sylvester
  • Jean-Pierre Pignon
چکیده

BACKGROUND Several trials have studied the role of unconventional fractionated radiotherapy in head and neck squamous cell carcinoma, but the effect of such treatment on survival is not clear. The aim of this meta-analysis was to assess whether this type of radiotherapy could improve survival. METHODS Randomised trials comparing conventional radiotherapy with hyperfractionated or accelerated radiotherapy, or both, in patients with non-metastatic HNSCC were identified and updated individual patient data were obtained. Overall survival was the main endpoint. Trials were grouped in three pre-specified categories: hyperfractionated, accelerated, and accelerated with total dose reduction. FINDINGS 15 trials with 6515 patients were included. The median follow-up was 6 years. Tumours sites were mostly oropharynx and larynx; 5221 (74%) patients had stage III-IV disease (International Union Against Cancer, 1987). There was a significant survival benefit with altered fractionated radiotherapy, corresponding to an absolute benefit of 3.4% at 5 years (hazard ratio 0.92, 95% CI 0.86-0.97; p=0.003). The benefit was significantly higher with hyperfractionated radiotherapy (8% at 5 years) than with accelerated radiotherapy (2% with accelerated fractionation without total dose reduction and 1.7% with total dose reduction at 5 years, p=0.02). There was a benefit on locoregional control in favour of altered fractionation versus conventional radiotherapy (6.4% at 5 years; p<0.0001), which was particularly efficient in reducing local failure, whereas the benefit on nodal control was less pronounced. The benefit was significantly higher in the youngest patients (hazard ratio 0.78 [0.65-0.94] for under 50 year olds, 0.95 [0.83-1.09] for 51-60 year olds, 0.92 [0.81-1.06] for 61-70 year olds, and 1.08 [0.89-1.30] for over 70 year olds; test for trends p=0.007). INTERPRETATION Altered fractionated radiotherapy improves survival in patients with head and neck squamous cell carcinoma. Comparison of the different types of altered radiotherapy suggests that hyperfractionation has the greatest benefit.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

DOES HYPERFRACTIONATED RADIOTHERAPY CHANGE THE OUTCOME OF HEAD AND NECK CANCER? A TRIAL COMPARING CONVENTIONAL WITH HYPERFRACTIONATED RADIOTHERAPY

The optimal fractionation schedule for radiotherapy of head and neck cancer has been controversial. The objective of this randomized trial was to test the efficacy of hyperfractionation vs. standard fractionation. Patients with squamous cell carcinoma of head and neck organs were randomly assigned to receive radiotherapy delivered with A) standard fractionation at 2 Gy/fraction/day, 5 days...

متن کامل

Concomitant chemoradiotherapy versus altered fractionation radiotherapy in the radiotherapeutic management of locoregionally advanced head and neck squamous cell carcinoma: An adjusted indirect comparison meta-analysis.

BACKGROUND Treatment intensification by using chemoradiotherapy (CRT) or altered fractionation radiotherapy (RT) improves outcomes in locoregionally advanced head and neck squamous cell carcinoma (HNSCC). METHODS Two comprehensive meta-analyses with similar control arms (conventionally fractionated RT) were compared indirectly. RESULTS The hazard ratio (HR) of death with 95% confidence inte...

متن کامل

A Review on the Efficacy of Chemotherapy in Locally Advanced Head and Neck Cancers

Background and Aims: Chemotherapy is utilized as a part of combined-modality programs to achieve organ preservation and improve survival in patients with locally advanced head and neck cancer. Combinedmodality protocols can be used in three forms: a) neoadjuvant induction chemotherapy before definitive surgery or radiotherapy; b) concomitant chemoradiotherapy; and c) sequential therapy consisti...

متن کامل

Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer.

BACKGROUND The purpose of this study was to determine the feasibility and efficacy of hyperfractionated accelerated radiotherapy (HFRCB) combined with simultaneous chemotherapy with weekly cisplatin (CDDP) in locally advanced inoperable head and neck cancer. METHODS From August 1999 to December 2002, 37 patients (median age, 59 years) with Union Internationale Contre le Cancer stage III (n = ...

متن کامل

Concurrent weekly docetaxel and hyperfractionated radiotherapy for advanced head and neck cancer.

BACKGROUND This study was designed to evaluate the concomitant use of weekly docetaxel and hyperfractionated radiotherapy for the treatment of head and neck cancer (HNC). PATIENTS AND METHODS Twenty-five patients with advanced squamous cell HNC were treated with hyperfractionated radiotherapy (72 Gy at 1.2 Gy twice per day) and weekly chemotherapy with docetaxel (10 mg/m2). RESULTS Toxicity...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Lancet

دوره 368 9538  شماره 

صفحات  -

تاریخ انتشار 2006